Oxygen-permeable microwell device maintains islet mass and integrity during shipping

Darling M. Rojas-Canales; Michaela Waibel; Aurelien Forget; Daniella Penko; Jodie Nitschke; Fran J. Harding; Bahman Delalat; Anton Blencowe; Thomas Loudovaris; Shane T. Grey; Helen E. Thomas; Thomas W.H. Kay; Chris J. Drogemuller; Nicolas H. Voelcker; Patrick T. Coates

doi:10.1530/EC-17-0349

Oxygen-permeable microwell device maintains islet mass and integrity during shipping

Darling M. Rojas-Canales, Michaela Waibel, Aurelien Forget, Daniella Penko, Jodie Nitschke, Fran J. Harding, Bahman Delalat, Anton Blencowe, Thomas Loudovaris, Shane T. Grey, Helen E. Thomas, Thomas W.H. Kay, Chris J. Drogemuller, Nicolas H. Voelcker, Patrick T. Coates

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Islet transplantation is currently the only minimally invasive therapy available for patients with type 1 diabetes that can lead to insulin independence; however, it is limited to only a small number of patients. Although clinical procedures have improved in the isolation and culture of islets, a large number of islets are still lost in the pre-transplant period, limiting the success of this treatment. Moreover, current practice includes islets being prepared at specialized centers, which are sometimes remote to the transplant location. Thus, a critical point of intervention to maintain the quality and quantity of isolated islets is during transportation between isolation centers and the transplanting hospitals, during which 20–40% of functional islets can be lost. The current study investigated the use of an oxygen-permeable PDMS microwell device for long-distance transportation of isolated islets. We demonstrate that the microwell device protected islets from aggregation during transport, maintaining viability and average islet size during shipping.

Original language	English (US)
Pages (from-to)	490-503
Number of pages	14
Journal	Endocrine Connections
Volume	7
Issue number	3
DOIs	https://doi.org/10.1530/EC-17-0349
State	Published - Mar 2018
Externally published	Yes

Keywords

Hypoxia
Islet
Microwell
Shipping
Transplantation

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1530/EC-17-0349

Cite this

Rojas-Canales, D. M., Waibel, M., Forget, A., Penko, D., Nitschke, J., Harding, F. J., Delalat, B., Blencowe, A., Loudovaris, T., Grey, S. T., Thomas, H. E., Kay, T. W. H., Drogemuller, C. J., Voelcker, N. H., & Coates, P. T. (2018). Oxygen-permeable microwell device maintains islet mass and integrity during shipping. Endocrine Connections, 7(3), 490-503. https://doi.org/10.1530/EC-17-0349

Rojas-Canales, DM, Waibel, M, Forget, A, Penko, D, Nitschke, J, Harding, FJ, Delalat, B, Blencowe, A, Loudovaris, T, Grey, ST, Thomas, HE, Kay, TWH, Drogemuller, CJ, Voelcker, NH & Coates, PT 2018, 'Oxygen-permeable microwell device maintains islet mass and integrity during shipping', Endocrine Connections, vol. 7, no. 3, pp. 490-503. https://doi.org/10.1530/EC-17-0349

@article{903183193bbe457bacfc3b9b1437a4f7,

title = "Oxygen-permeable microwell device maintains islet mass and integrity during shipping",

abstract = "Islet transplantation is currently the only minimally invasive therapy available for patients with type 1 diabetes that can lead to insulin independence; however, it is limited to only a small number of patients. Although clinical procedures have improved in the isolation and culture of islets, a large number of islets are still lost in the pre-transplant period, limiting the success of this treatment. Moreover, current practice includes islets being prepared at specialized centers, which are sometimes remote to the transplant location. Thus, a critical point of intervention to maintain the quality and quantity of isolated islets is during transportation between isolation centers and the transplanting hospitals, during which 20–40\% of functional islets can be lost. The current study investigated the use of an oxygen-permeable PDMS microwell device for long-distance transportation of isolated islets. We demonstrate that the microwell device protected islets from aggregation during transport, maintaining viability and average islet size during shipping.",

keywords = "Hypoxia, Islet, Microwell, Shipping, Transplantation",

author = "Rojas-Canales, \{Darling M.\} and Michaela Waibel and Aurelien Forget and Daniella Penko and Jodie Nitschke and Harding, \{Fran J.\} and Bahman Delalat and Anton Blencowe and Thomas Loudovaris and Grey, \{Shane T.\} and Thomas, \{Helen E.\} and Kay, \{Thomas W.H.\} and Drogemuller, \{Chris J.\} and Voelcker, \{Nicolas H.\} and Coates, \{Patrick T.\}",

note = "Funding Information: This work was funded by the Cooperative Research Centre for Cell Therapy Manufacturing. Funding Information: The authors thank Prof. Hans Griesser, Dr Thomas Michl and Marek Jasieniak for providing access to plasma reactor and protocol for the polymer coating. Christina Tan for her technical help and the islet isolation team at St Vincent{\textquoteright}s Institute (supported by the Operational Infrastructure Support Scheme of the Government of Victoria). CCET is supported by grants from the Hospital Research Foundation and Kidney Transplant Diabetes Research Australia. The authors would like to acknowledge and thank Donate Life Australia and the donor families who provided consent for islets for human research. The whole team would like to thank the CRC-CTM for funding this research. Nicolas H Voelcker and Patrick T Coates: Senior authors. Publisher Copyright: {\textcopyright} 2018 The authors.",

year = "2018",

month = mar,

doi = "10.1530/EC-17-0349",

language = "English (US)",

volume = "7",

pages = "490--503",

journal = "Endocrine Connections",

issn = "2049-3614",

publisher = "BioScientifica Ltd.",

number = "3",

}

TY - JOUR

T1 - Oxygen-permeable microwell device maintains islet mass and integrity during shipping

AU - Rojas-Canales, Darling M.

AU - Waibel, Michaela

AU - Forget, Aurelien

AU - Penko, Daniella

AU - Nitschke, Jodie

AU - Harding, Fran J.

AU - Delalat, Bahman

AU - Blencowe, Anton

AU - Loudovaris, Thomas

AU - Grey, Shane T.

AU - Thomas, Helen E.

AU - Kay, Thomas W.H.

AU - Drogemuller, Chris J.

AU - Voelcker, Nicolas H.

AU - Coates, Patrick T.

N1 - Funding Information: This work was funded by the Cooperative Research Centre for Cell Therapy Manufacturing. Funding Information: The authors thank Prof. Hans Griesser, Dr Thomas Michl and Marek Jasieniak for providing access to plasma reactor and protocol for the polymer coating. Christina Tan for her technical help and the islet isolation team at St Vincent’s Institute (supported by the Operational Infrastructure Support Scheme of the Government of Victoria). CCET is supported by grants from the Hospital Research Foundation and Kidney Transplant Diabetes Research Australia. The authors would like to acknowledge and thank Donate Life Australia and the donor families who provided consent for islets for human research. The whole team would like to thank the CRC-CTM for funding this research. Nicolas H Voelcker and Patrick T Coates: Senior authors. Publisher Copyright: © 2018 The authors.

PY - 2018/3

Y1 - 2018/3

N2 - Islet transplantation is currently the only minimally invasive therapy available for patients with type 1 diabetes that can lead to insulin independence; however, it is limited to only a small number of patients. Although clinical procedures have improved in the isolation and culture of islets, a large number of islets are still lost in the pre-transplant period, limiting the success of this treatment. Moreover, current practice includes islets being prepared at specialized centers, which are sometimes remote to the transplant location. Thus, a critical point of intervention to maintain the quality and quantity of isolated islets is during transportation between isolation centers and the transplanting hospitals, during which 20–40% of functional islets can be lost. The current study investigated the use of an oxygen-permeable PDMS microwell device for long-distance transportation of isolated islets. We demonstrate that the microwell device protected islets from aggregation during transport, maintaining viability and average islet size during shipping.

AB - Islet transplantation is currently the only minimally invasive therapy available for patients with type 1 diabetes that can lead to insulin independence; however, it is limited to only a small number of patients. Although clinical procedures have improved in the isolation and culture of islets, a large number of islets are still lost in the pre-transplant period, limiting the success of this treatment. Moreover, current practice includes islets being prepared at specialized centers, which are sometimes remote to the transplant location. Thus, a critical point of intervention to maintain the quality and quantity of isolated islets is during transportation between isolation centers and the transplanting hospitals, during which 20–40% of functional islets can be lost. The current study investigated the use of an oxygen-permeable PDMS microwell device for long-distance transportation of isolated islets. We demonstrate that the microwell device protected islets from aggregation during transport, maintaining viability and average islet size during shipping.

KW - Hypoxia

KW - Islet

KW - Microwell

KW - Shipping

KW - Transplantation

UR - https://www.scopus.com/pages/publications/85052317401

UR - https://www.scopus.com/inward/citedby.url?scp=85052317401&partnerID=8YFLogxK

U2 - 10.1530/EC-17-0349

DO - 10.1530/EC-17-0349

M3 - Article

AN - SCOPUS:85052317401

SN - 2049-3614

VL - 7

SP - 490

EP - 503

JO - Endocrine Connections

JF - Endocrine Connections

IS - 3

ER -

Oxygen-permeable microwell device maintains islet mass and integrity during shipping

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this